Market Overview

UPDATE: Piper Jaffray Reduces PT to $67 on Albemarle on Bromine Derivatives Visibility

Share:
Related ALB
Which Chemical Company Will Be Hit Hardest By The Supreme Court's Mercury Ruling?
Earnings Scheduled For May 6, 2015
Albemarle Shifting Corporate Headquarters to Charlotte (Zacks)

Piper Jaffray reiterated its Overweight rating on Albemarle (NYSE: ALB) and lowered its price target from $72 to $67.

Piper Jaffray commented, "At this point, Albemarle is largely a 2013 story, with Fine Chemistry doubling capacity to keep pace and NBPT exhibiting robust growth, and Catalysts expecting a solid lead-in to 2013 on higher HPC volumes y/y. The larger question marks are olumes and pricing for bromine derivatives, for which we expect more clarity post Chinese New Year."

Albemarle closed at $55.33 on Friday.

Latest Ratings for ALB

DateFirmActionFromTo
Aug 2015MacquarieMaintainsOutperform
Aug 2015SunTrust Robinson HumphreyUpgradesNeutralBuy
Jul 2015BB&T CapitalInitiates Coverage onBuy

View More Analyst Ratings for ALB
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (ALB)

View Comments and Join the Discussion!

Get Benzinga's Newsletters